Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tectonic Therapeutic, Inc. (TECX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: TECX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $82.33
1 Year Target Price $82.33
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 140.04% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 384.84M USD | Price to earnings Ratio - | 1Y Target Price 82.33 |
Price to earnings Ratio - | 1Y Target Price 82.33 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 13.70 - 61.07 | Updated Date 07/9/2025 |
52 Weeks Range 13.70 - 61.07 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.89% | Return on Equity (TTM) -41.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 81226410 | Price to Sales(TTM) - |
Enterprise Value 81226410 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18672500 | Shares Floating 8767116 |
Shares Outstanding 18672500 | Shares Floating 8767116 | ||
Percent Insiders 38.29 | Percent Institutions 59.27 |
Upturn AI SWOT
Tectonic Therapeutic, Inc.
Company Overview
History and Background
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing novel biologic therapies targeting G protein-coupled receptors (GPCRs). Founded to leverage insights into GPCR structure and function, the company aims to address unmet medical needs by creating targeted therapies.
Core Business Areas
- GPCR-Targeted Biologics Discovery: Development of therapeutic antibodies and other biologics targeting GPCRs. Focus on novel approaches to modulate GPCR signaling.
- Drug Development and Clinical Trials: Conducting preclinical research, clinical trials, and pursuing regulatory approvals for drug candidates. This includes lead optimization, formulation development, and manufacturing.
- Technology Platform Development: Advancing their GEODeS platform for GPCR drug discovery. This includes improving computational modeling, protein engineering, and high-throughput screening capabilities.
Leadership and Structure
The leadership team consists of experienced professionals in drug discovery, development, and business strategy. The organizational structure includes research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- TECT-001 (GPCR antibody): TECT-001 is Tectonic's lead program, focusing on a specific GPCR target in oncology. Currently in preclinical development. Market share is not yet applicable as it is not on the market. Competitors depend on the indication and target of TECT-001. Large Pharma companies like Roche (RHHBY), Novartis (NVS), and smaller biotech companies working on GPCR-targeted therapies are potential competitors.
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth with advances in drug discovery technologies and increasing investment in novel therapeutics. GPCR-targeted therapies represent a significant market opportunity due to their involvement in various diseases.
Positioning
Tectonic Therapeutic, Inc. is positioned as an innovator in GPCR-targeted biologics, leveraging its GEODeS platform to discover and develop differentiated therapies. Its competitive advantages include a focus on complex GPCR targets and innovative drug discovery approaches.
Total Addressable Market (TAM)
The TAM for GPCR-targeted therapies is substantial, estimated to be in the tens of billions of dollars, depending on the specific indication and market penetration. Tectonic is positioned to capture a portion of this TAM by developing novel biologics for high-value targets.
Upturn SWOT Analysis
Strengths
- Proprietary GEODeS platform for GPCR drug discovery
- Experienced leadership team
- Focus on difficult-to-drug GPCR targets
- Potential for first-in-class biologics
Weaknesses
- Early-stage pipeline with significant development risk
- Reliance on successful clinical trial outcomes
- Dependence on raising capital to fund operations
- Limited commercial infrastructure
Opportunities
- Partnering with larger pharmaceutical companies
- Expanding the GEODeS platform to new GPCR targets
- Securing regulatory approvals for lead candidates
- Addressing unmet medical needs in various diseases
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- LLY
- NVS
- MRK
- VRTX
Competitive Landscape
Tectonic Therapeutic, Inc. faces competition from established pharmaceutical companies with existing GPCR-targeted therapies and other biotechnology companies developing novel approaches. Tectonic aims to differentiate itself through its GEODeS platform and focus on challenging GPCR targets.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by advancement of drug candidates through preclinical and clinical development, securing partnerships, and raising capital.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of products. Analyst estimates are not available without public trading history.
Recent Initiatives: Recent initiatives include advancing lead programs towards clinical trials, expanding the GEODeS platform, and exploring potential partnerships.
Summary
Tectonic Therapeutic, Inc. is a preclinical stage biotechnology company focused on GPCR-targeted therapies, offering innovative approaches with its GEODeS platform. Its strengths lie in its technology and experienced team, but success hinges on clinical trial outcomes and securing funding. Threats include competition and regulatory hurdles, with opportunities arising from partnerships and platform expansion. Overall the company exhibits average fundamentals and has lots of oppourtunity, but needs to be aware of other public companies that can compete with them.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (if available)
- Industry reports
- Press releases
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated and may not be precise. The AI-based rating is based on a limited dataset and should be used as a reference point.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tectonic Therapeutic, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2018-06-21 | President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://tectonictx.com |
Full time employees 51 | Website https://tectonictx.com | ||
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.